BridgeBio real-world study shows Attruby cuts ATTR-CM clinical worsening risk 34% vs Pfizer’s tafamidis
BBIO•Separate comparative study planned for 2026 meeting
A separate electronic health record-based comparative study is slated for release at a 2026 medical meeting.
Peer-reviewed real-world study compares Attruby and tafamidis
BridgeBio reported peer-reviewed real-world study results in Cardiology and Therapy comparing its ATTR-CM drug Attruby to Pfizer’s tafamidis.
Claims-data analysis found Attruby patients were less likely to show early clinical worsening than those starting tafamidis.
Benefits appeared within weeks, supporting a potential argument for frontline use or switching from tafamidis in routine practice.
